Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK 482.60
+5.20 (1.09%)
Nov 4, 2026, 5:29 PM CET
STO:SOBI Financials Overview
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 31,971 | 28,238 | 26,027 | 22,123 | 18,790 | 15,529 |
Revenue Growth | 14.79% | 8.49% | 17.65% | 17.74% | 21.00% | 1.76% |
Gross Profit Gross Profit Growth | 25,016 | 22,271 | 20,310 | 17,160 | 14,377 | 12,045 |
Operating Income Operating Income Growth | 9,869 | 8,058 | 5,823 | 4,653 | 4,520 | 3,794 |
Net Income Net Income Growth | 6,628 | 478 | 3,885 | 2,409 | 2,638 | 2,679 |
Earnings Per Share EPS Growth | 18.80 | 1.37 | 11.24 | 7.39 | 8.84 | 9.03 |
EPS Growth | 50500.47% | -87.81% | 52.10% | -16.39% | -2.11% | -17.16% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Immunology Immunology Growth | 8,217 | 7,809 | 8,332 | 7,635 | 6,679 | 5,780 |
Haematology Haematology Growth | 22,225 | 19,116 | 16,429 | 13,370 | 10,831 | 8,536 |
Specialty Care Specialty Care Growth | 1,528 | 1,312 | 1,267 | 1,119 | 1,280 | 1,213 |
Total Total Growth | 31,970 | 28,237 | 26,028 | 22,124 | 18,790 | 15,529 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,005 | 1,041 | 1,140 | 904 | 1,361 | 1,045 |
Total Debt Total Debt Growth | 16,154 | 11,495 | 16,735 | 20,485 | 9,101 | 10,906 |
Net Cash (Debt) Net Cash Growth | -15,149 | -10,454 | -15,595 | -19,581 | -7,740 | -9,861 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -42.99 | -30.07 | -45.13 | -60.07 | -25.93 | -33.22 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 7,889 | 8,565 | 7,388 | 4,470 | 4,576 | 5,470 |
Capital Expenditures CapEx Growth | -23 | -40 | -170 | -873 | -72 | -47 |
Free Cash Flow Free Cash Flow Growth | 7,866 | 8,525 | 7,218 | 3,597 | 4,504 | 5,423 |
Free Cash Flow Growth | 7.25% | 18.11% | 100.67% | -20.14% | -16.95% | 11.01% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 78.25% | 78.87% | 78.03% | 77.57% | 76.51% | 77.56% |
Operating Margin | 30.87% | 28.54% | 22.37% | 21.03% | 24.05% | 24.43% |
Pretax Margin | 25.97% | 0.12% | 16.93% | 13.36% | 17.67% | 21.22% |
Profit Margin | 20.73% | 1.69% | 14.93% | 10.89% | 14.04% | 17.25% |
FCF Margin | 24.60% | 30.19% | 27.73% | 16.26% | 23.97% | 34.92% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 25.67 | 239.96 | 28.37 | 38.07 | 24.52 | 20.66 |
Forward PE | 20.85 | 19.17 | 25.06 | 32.77 | 19.95 | 24.22 |
P/FCF Ratio | 21.16 | 13.46 | 15.27 | 25.50 | 14.36 | 10.21 |
PS Ratio | 5.21 | 4.06 | 4.24 | 4.14 | 3.44 | 3.56 |